Time for Live Meeting
Nov 12 & 13
San Francisco 11 am – 1 pm
Chicago 1-3 pm
New York 2-4 pm
Rio de Janeiro 4-6 pm
London 19:00-21:00
Berlin 20:00-22:00
Nov 13 & 14
Sydney 6-8 am
Day 1: November 12
Hour 1: Signaling and Vascular Biology
Moderator: Mark Ginsberg, UCSD
Additional Discussion Participants: Angela Glading, Salim Seyfried
Panelists and Presentations to be Discussed:
CCM2 deficient endothelial cells undergo a mechanical reprogramming into a senescence associated with a secretory phenotype – Eva Faurobert, Institute for Advanced Biosciences, University Grenoble Alpes, INSERM
High levels of receptor tyrosine kinases in CCM3-deficient cells increase their susceptibility to tyrosine kinase inhibition – Miriam Sartages & Juan Zalvide, University of Santiago de Compostela
Stabilization of adherens junctions by KRIT1 requires junctional localization and an open conformation – Harsha Swamy, University of Rochester
CCM signaling complex (CSC) is a master regulator governing homeostasis of progestins and their mediated signaling cascades – Johnathan Abou-Fadel and Jun Zhang, Texas Tech University Health Science Center El Paso
Hour 2: Animal Models of CCM
Moderator: Kevin Whitehead, University of Utah
Additional Discussion Participants: Mark Ginsberg, Maria Grazia Lampugnani, Miguel Lopez Ramirez, Doug Marchuk
Panelists and Presentations to be Discussed:
Abortive Intussusceptive Angiogenesis Causes Multi-Cavernous Vascular Malformations – Wenqing Li, UCSD
Familial and Sporadic CCMs Follow a Genetic Two-Hit Model – Daniel Snellings, Duke University
Investigating CCM mosaicism through microscopy and single-cell RNA sequencing – Matthew Detter, Duke University
Mapping endothelial-cell diversity in cerebral cavernous malformations at single-cell resolution – Lei Liu Conze, Uppsala University
Day 2: Friday, November 13
Hour 1: Pre-Clinical Studies and Biomarkers
Moderator: Doug Marchuk, Duke University
Panelists and Presentations to be Discussed:
Propranolol reduces lesions and rescues barrier function in cerebral cavernous malformations: a preclinical study – Peetra Magnusson, Uppsala University
Propranolol Inhibits Cavernous Vascular Malformations by β1 Adrenergic Receptor Antagonism – Robert Shenkar, University of Chicago and Wenqing Li, UCSD
Limiting clonal expansion of cerebral cavernous malformations using sonodynamic therapy with focused ultrasound – Khadijeh Sharifi and Petr Tvrdik, University of Virginia
Human Homologs of Differentially Expressed Plasma MicroRNAs In Preclinical Murine Models Target Fundamental Mechanisms Of CCM – Sharbel Romanos, University of Chicago
Circulating Plasma Biomarkers Associated with Familial Cerebral Cavernous Malformations – Shantel Weinsheimer, UCSF
Lesional perfusion and permeability are diagnostic and prognostic biomarkers of cavernous malformation with symptomatic hemorrhage – Je Yeong Sone, University of Chicago
Hour 2: Natural History, Clinical Studies, Clinical Trials, and Future Directions
Moderator: Issam Awad, University of Chicago
Panelists and Presentations to be Discussed:
Brain Vascular Malformation Consortium (BVMC): Updates on CCM Project – Helen Kim, UCSF
Validation of The Brainstem Cavernous Malformation (BSCM) Grading System – Joshua Catapano, Barrow Neurological Institute
Influence of Pregnancy on Hemorrhage Risk in Women with Cerebral and Spinal Cavernous Malformations – Kelly Flemming, Mayo Clinic
Discovery & Development of CVT-100069 & CVT-100077, Potent and Selective ROCK Inhibitors – Matthew Lee, Cervello Therapeutics
Propranolol treatment for Familial Cerebral Cavernous Malformation: an update on Treat_CCM Clinical Trial – Francesca Lazzaroni, IFOM Milan
Update on CASH TR and AT CASH EPOC Trial – Issam Awad, University of Chicago
REC-994: Moving from Phase I to Phase II – Ron Alfa, Recursion Pharmaceuticals
Additional Presentation (video only)
Update on Alliance to Cure Cavernous Malformation Initiatives and CCM2 Exon 2-10 Deletion Project – Connie Lee, Alliance to Cure Cavernous Malformation
To request registration information, please contact Connie Lee at clee@alliancetocure.org. Attendance is restricted. Please see Who May Attend? for more information.
